Startseite>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>E3 Ligase Ligand-Linker Conjugates 20

E3 Ligase Ligand-Linker Conjugates 20 (Synonyms: Cereblon Ligand-Linker Conjugates 2; E3 Ligase Ligand-Linker Conjugates 20)

Katalog-Nr.GC33390

E3-Ligase-Ligand-Linker-Konjugate 20 (Cereblon-Ligand-Linker-Konjugate 2), ein synthetisiertes E3-Ligase-Ligand-Linker-Konjugat, das den auf Thalidomid basierenden Cereblon-Liganden und einen Linker enthÄlt, kann bei der Synthese von PROTACs verwendet werden.

Products are for research use only. Not for human use. We do not sell to patients.

E3 Ligase Ligand-Linker Conjugates 20 Chemische Struktur

Cas No.: 1950635-15-0

Größe Preis Lagerbestand Menge
100mg
321,00 $
Auf Lager
500mg
1.241,00 $
Auf Lager
1g
2.298,00 $
Auf Lager
2g
3.218,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

E3 Ligase Ligand-Linker Conjugates 20 is a degron-linker (refer to Compound DL7-TL). The PROTAC linker is bound lo at least one targeting ligand.

Degron-linker-targeting ligand, wherein the linker is covalently bound lo at least one degron and at least one targeting ligand, the degron is a compound capable of binding to an ubiquitin ligase such as an E3 ubiquitin ligase (e g, cereblon), and the targeting ligand is capable of binding to the targeted protein (s)[1].

[1]. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.

Bewertungen

Review for E3 Ligase Ligand-Linker Conjugates 20

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for E3 Ligase Ligand-Linker Conjugates 20

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.